Edi) «0:5

(D3131 3WZZ’VW 712:, ammlfm

Patien: Mamet I . Med Rec 1:: 4‘

Nos) 3680/3

., , ,_ ‘ r__. _ cgﬁéf - __‘ ,
.. 4- 53411.- “; emmdb‘lr/

Requested By
Ordered By a

Report Name:

Burg Path Case » STATUS: Final

'*SEE NOTE Collect/Perform:
Ordered By: Ordered Date;
Department:

Physician Who Performed Procedure
Requesting Physiciax

Attending Pathologist

DIAGNOSIS:

1. Uterus. aervix, bilateral ovaries and fallopian cubes, hysterectomy and
bilateral salpingo—oophorectomy:

— Histologic Type: Endometrioid adenocarcinoma
- Histologic Grade: F160 grade 2 (6-50% solid non—squamous growth)
- Nuclear grade: Low grade to intermediate grade
- Tumor Size:
Greatest dimension: 4cm; other two dimensions: 2.5 x 1.2 cm
, Specimen Integrity: Intact
— Tumor Site: Anterior fundua
- Myometrial Invasion: Approximately 5%
Depth of invasion: l mm
Myometrial thickness: 18 mm
- Cervical Stromal Invasion: Absent
— Lymph-vascular Invasion: Absent
. Paracervical Soft Tissue Margin: Negative
- Other Tissues/Organs Involved: None
, Peritoneal Aecitic Fluid: Pelvic washing (cytospins), NEGATIVE FOR
MALIGNANT CELLS

- Regional Lymph Node Metastasis:

Pelvic nodes: 0/5 (part 2 and 3)

Para-aortic nodes: Cannot be assessed
- Distant Metastasis: Cannot be determined
- Additional Pathologic Findings: Uterine leiomyomas with infarction and
degenerative changes, inactive endomecrium with adenomyosis. RIGHT and
LEFT ovaries with no neoplasm seen. Fallopian tubes with paratubal cysts.
Cervical tissue with nabothian cysts.

”iii/mam , Lia/u 0511.3
)fQSkﬁi/l 9‘

UUID:3E66FA38-ODB7-47CA-A72D-63C0619A2182
TCGA-PG-AQIS-OlA-PR R

muIIIIIIIﬁI‘iI‘T‘I‘inte
Ill||||||||||||||||||||l|||||||||||||||l|||I|
III||||||||||||||||||||||||||||l|||IIIIIIIIIIIIIIIIIIIIIIIIIIIII
III|||||||||||||||||||||||||IIlll|||||||||||IIIIII|||||||||||

d

mm

Patient Name¢ ”1; Med Rec #
. ”a? .» “

Requested By
Ordered I

Report Name:

- Ancillary Studies:
ER: Positive (approximately 70*)
PR: Positive (approximately 90%)
Other: Immunohistochemical stain for PS3 ie negative
~ AJCC Petholcgic Staging: pTla No M Not applicable: F160: IA

2. LEFT pelvic lymph nodes, dissection:

- Four lymph nodes, negative for carcinoma (0/4).

3. RIGHT pelvic lymph nodes, dissection:

. One lymph node, negative for carcinoma (0/1).

COMMENT : None

Case reviewed with one or more pathologistts) in the Department of
Pathology, who concurred with the above diagnosis.

u:ua=u:=aamn=:nn-sa3::=-=ann-nn-nt-unuunnuu—gga=

 

=~n====a==s==s==szn==

CLINICAL INFORMATION:
Pelvic mass.

GROSS DESCRIPTION:

1. The specimen is received fresh for intraoperative consultation ann
labeled uterus, cervix, tubes and overies. It consists Of a uterus. cervix
with attached bilateral ovary and fallopian tubes. The specimen weighs 279
gram in toto ans with following measurements: 10.5 cm from fundus ta
exocervix: 5.0 cm from cornu to cornu; 5.0 cm from anterior to posterior.
The right ovary and fallopian tube measures 3.5 x 1.8 x 1.4 cm and 10 x 0.6
x 0.5 cm respectively. The left ovary and ﬁallopian tube measures 2.7 x 1.7
x 1.5 cm and 3.5 x 0.6 x 0.5 cm respectively. The exocervix is tan white
and smooth. On opening, the endocervical canal measures 3.0 cm in length
and 0.7 cm across. It has a tan 2.5 cm polyp located at anterior aspect.
The endometrial cavity measuIES 6.5 cm in length and 3.8 cm from cornu to
cornu. The endometrium is tan and polyploid mess on the anterior Eundus.
measuring 4.0 x 2.5 x 1.2 cm. The mass appears to be invasion of the
underlying mucosa. The myomettium measures 2.5 cm in maximum thickness. The
mass is located 4.0 cm from the lower uterine segment. The anterior
endometrium is focally thickened, measuring up to 0.6 cm. there are four
tan white, rubbery and well—circumscribed masses located subserosa and

«30134,!

Patient Nameﬁwﬂ‘ _ . __.,h . Med Rec 38: xi
E

Requested By
Ordered B

Report Name

intramural, nmasuring from 2.0 cm up to 6.5 cm in greatest dimension. No
degeneration identified, grossly. The right and left ovaries have a can
white smooth outer surface with several white corpora albicantia. The both
fallopian tubes have-grossly identifiable pinpoint lumen with fimbriated
ends, Representative sections are submitted as follows:

A: Frozen section from endometrial tumor

E: Tumor with deepest invasion

C-F: Tumor (50% of the tumor is submitted)

GwH: Thickened anterior endometrium

I: Anterior lower segment of the endomeCrium

a: Posterior lower segment of the endometrium

K: Anterior cervix with polyp

L: Anterior cervix

M—O: Entire right ovary

P—S: Entire right fallopian tube

TmV: Entire left ovary

w-Y: Entire left fallopian tube

Z—AE: masaes

Intraoparative consult: Representative section from the fundus mass showing
endometrial adenocarcinoma. no definitive invasion seen. Reported to

2. The specimen is received fresh and labeled left pelvic lymph node. It
consists of a piece of tan-red soft tissue, measuring 3.5 x 2.5 x 1.0 cm
the specimen is serially sectioned and has three possible lymph nodee
identified, measuring up to 2.7 cm in greatest dimension. The specimen is
entirely submitted as follows:

A: one lymph node
B: One lymph node
C: One lymph node
D: Adipose tisaue

3. The specimen is received fresh and labeled RIGHT pelvic lymph node. It
consists of a piece of tan-red soft tissue, measuring 3.0 x 2.0 x 0.8 cm.
The specimen is serially sectioned and one lymph node identified, measuring

up to 0.7 cm in greatest dimension. The specimen is entirely submitted as
follows:

A: One lymph node
8-D: Adipose tissue

50%

’_ am ,1,

Patient Namef ff/_ . ‘ . Med Rec 9‘
“El.

 

Requested By
Ordered B}

Report Name

The following special studies were performed on this case and the
interpretation ia incorporated in the diagnostic report above:
1xER (FDR DIAGNOSIS), leR (FOR DIAGNOSIS), 1xPs3

** Electronic signature **
*«Electronically Signed Out by

I certify that I personally conducted the diagnostic evaluation of the
above specimenls) and have rendered the final diagnosis(es).

Note: The histology. immunochemistry and in situ hvbridizarinn rnmnonents
for this case were performed at

The Attending Pathologist reviewed this case and made the diagnosis.
Where applicable, immunohistochemistry and in situ hybridization tests were
developed and rhn “-V‘ﬁvmaﬁnn rharaCtEIistiCE determined hv the

have not been cleared or approved by the us Food and Drug Administration
and the results should be correlated with other clinical and laboratory
data. Appropriate controls were performed for all immunohistochemistry. in
situ hybridization and histochemical tests.

Canada

Tumor Site

HIPAA

 

